文献速递肾小球疾病

CFHR3*B单倍型增强补体激活并增加IgA肾病风险

CFHR3*B Haplotype, Complement Activation, and Risk of IgA Nephropathy.
PubMed 文献 · J Am Soc Nephrol · 2025-12-15

研究通过1108例IgA肾病患者和630例健康对照的遗传分析,发现CFHR3*B单倍型及其纯合基因型在患者中显著富集,与较低循环C3水平和较多肾小球C3沉积相关。功能实验表明rs446868A增强CFHR3转录,rs138675433T(FHR3 241Ser)增强C3b结合和补体激活,促进IgA沉积诱导的补体激活。

要点

  • CFHR3*B单倍型是IgA肾病易感变异,通过增强补体激活起作用。
  • rs446868A提高CFHR3转录,携带者循环FHR3水平升高。
  • FHR3 241Ser增强C3b结合和补体激活,加速IgA沉积诱导的补体激活。

核心结论

  • CFHR3*B单倍型是IgA肾病诊断的易感变异,通过rs446868A增强转录和rs138675433T增强FHR3功能来加速补体激活。

研究设计与样本

  • 遗传关联研究纳入1108例IgA肾病患者和630例健康对照,并进行荧光素酶活性实验和重组蛋白功能实验。

主要发现

  • CFHR3*B单倍型和CFHR3*BB基因型在IgA肾病患者中显著富集。
  • CFHR3*BB基因型与较低循环C3水平和较多肾小球C3沉积相关。
  • 荧光素酶实验显示CFHR3*B单倍型增强转录活性,rs446868为功能调控变异。
  • 携带CFHR3*BB基因型的患者循环FHR3水平升高。
  • FHR3 241Ser显著增强C3b结合能力和因子H失调活性,促进C3转化酶形成和溶血。

临床怎么用

  • CFHR3*B单倍型及其功能变异可作为IgA肾病易感性评估的遗传标志物。
  • 携带CFHR3*BB基因型的患者可能表现为更明显的补体激活,需关注补体相关指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KEY POINTS: CFHR3*B haplotype was a susceptibility variant for IgA nephropathy diagnosis by enhancing complement activation. The rs446868A variant in CFHR3*B elevated CFHR3 transcription and was associated with higher circulating FHR3 levels in patients with IgA nephropathy. FHR3241Ser variant enhanced C3b binding and complement activation, accelerating IgA deposition-induced complement activation in IgA nephropathy. BACKGROUND: Complement activation is involved in IgA nephropathy. We previously identified that genetic deletion of CFHR3 and CFHR1 confers protection against IgA nephropathy by modulating complement activation. In addition, the CFHR3*B haplotype (rs385390C/rs446868A/rs138675433T/rs149352569T) has been linked to elevated CFHR3 transcription and higher risk of atypical hemolytic uremic syndrome. METHODS: We evaluated the association between the CFHR3*B haplotype and IgA nephropathy susceptibility by using genetic analysis of 1108 patients with IgA nephropathy and 630 healthy controls. Luciferase activity assays were performed to assess the transcriptional activity of CFHR3*B haplotype. The coding variant rs138675433 (FHR3 241Pro versus FHR3 241Ser ) was assessed using recombinant proteins to determine its effect on complement regulation. RESULTS: The CFHR3*B haplotype and CFHR3*BB genotype were significantly enriched in patients with IgA nephropathy. The CFHR3*BB genotype correlated with lower circulating C3 levels and greater glomerular C3 deposition. Luciferase activity assays demonstrated enhanced transcription activity conferred by the CFHR3*B haplotype, with rs446868 identified as the functional regulatory variant. Patients carrying the CFHR3*BB genotype exhibited elevated circulating FHR3 levels. FHR3 241Ser exhibited significantly enhanced C3b-binding capacity and factor H deregulation activity, promoting accelerated C3 convertase formation and increased hemolysis. Furthermore, FHR3 241Ser augmented IgA deposition-induced complement activation on cultured mesangial cells in a dose-dependent manner. CONCLUSIONS: Our results identified CFHR3*B haplotype as a susceptibility variant for IgA nephropathy diagnosis by accelerating complement activation, through rs446868A enhancing transcription activity and rs138675433T augmenting FHR3 function.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Zhang Y, Zou H, Ni X, et al. CFHR3*B Haplotype, Complement Activation, and Risk of IgA Nephropathy. J Am Soc Nephrol. 2025. PMID: 41563799. doi:10.1681/ASN.0000000983

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。